A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
Jaime Monserrat Villatoro, Gina Mejía-Abril, Lucía Díaz García, Pablo Zubiaur, María Jiménez González, Guillermo Fernandez Jimenez, Inés Cancio, José Ramón Arribas, Carmen Suarez Fernández, Jesús Mingorance, Julio García Rodríguez, José Ramón Villagrasa Ferrer, Antonio J Carcas, Jesús Frías, Francisco Abad-Santos, Alberto M Borobia, Elena Ramírez
Pharmaceuticals, doi:10.3390/ph15010078
Data from several cohorts of coronavirus disease 2019 suggest that the most common comorbidities for severe COVID-19 disease are the elderly, high blood pressure, and diabetes; however, it is not currently known whether the previous use of certain drugs help or hinder recovery. This study aims to explore the association of previous hospitalisation use of medication on the mortality of COVID-19 disease. A retrospective case-control from two hospitals in Madrid, Spain, included all patients aged 18 years or above hospitalised with a diagnosis of COVID-19. A Propensity Score matching (PSM) analysis was performed. Confounding variables were considered to be age, sex, and the number of comorbidities. Finally, 3712 patients were included. Of these, 687 (18.5%) patients died (cases). The 22,446 medicine trademarks used previous to admission were classified according to the ATC, obtaining 689 final drugs; all of them were included in PSM analysis. Eleven drugs displayed a reduction in mortality: azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate. Eight final drugs displayed an increase in mortality: acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol. Medication associated with survival (anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with mortality show an interaction with the underlying conditions.
Conflicts of Interest: The authors declare no conflict of interest.
References
Al-Khafaji, Al-Duhaidahawi, Taskin Tok, Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1764392Atc/Ddd, None
Batiha, Gari, Elshony, Shaheen, Abubakar et al., Hypertension and its management in COVID-19 patients: The assorted view, Int. J. Cardiol. Cardiovasc. Risk Prev,
doi:10.1016/j.ijcrp.2021.200121Bean, Kraljevic, Searle, Bendayan, Pickles et al., Treatment with AVE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-site UK acute Hospital Trust, MedRxiv,
doi:10.1101/2020.04.07.20056788Borobia, Carcas, Arnalich, Álvarez-Sala, Monserrat-Villatoro et al., A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe, J. Clin. Med,
doi:10.3390/jcm9061733Cho, Lee, Kim, Kim, Kim et al., Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19, Sci. Rep,
doi:10.1038/s41598-020-72879-7Coupland, Dhiman, Morriss, Arthur, Barton et al., Antidepressant use and risk of adverse outcomes in older people: Population based cohort study, BMJ,
doi:10.1136/bmj.d4551De Abajo, Rodríguez-Martín, Lerma, Mejía-Abril, Aguilar et al., MED-ACE2-COVID-19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study, Lancet,
doi:10.1016/S0140-6736(20)31030-8Durojaiye, Clarke, Stamatiades, Wang, Repurposing cefuroxime for treatment of COVID-19: A scoping review of in silico studies, J. Biomol. Struct. Dyn,
doi:10.1080/07391102.2020.1777904Echeverría-Esnal, Martin-Ontiyuelo, Navarrete-Rouco, Cuscó, Ferrández et al., Azithromycin in the treatment of COVID-19: A review, Expert Rev. Anti Infect. Ther,
doi:10.1080/14787210.2020.1813024Fedele, De Francesco, Riso, Collo, Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview, Nutrition,
doi:10.1016/j.nut.2020.111016Feingold, Anawalt, Boyce, Chrousos, De Herder et al., Lipid and Lipoprotein Levels in Patients with COVID-19 Infections
Foundation, A Language and Environment for Statistical Computing; R Foundation for Statistical Computing
Garg, Kim, Whitaker, O'halloran, Cummings et al., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, Morb. Mortal. Wkly. Rep,
doi:10.15585/mmwr.mm6915e3Goyal, Choi, Pinheiro, Schenck, Chen et al., Clinical Characteristics of COVID-19 in New York City, N. Engl. J. Med,
doi:10.1056/NEJMc2010419Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med,
doi:10.1056/NEJMoa2002032Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin. Exp. Pharmacol. Physiol,
doi:10.1111/1440-1681.13488Hou, Ge, Li, Wang, He et al., Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis, Chem. Interact,
doi:10.1016/j.cbi.2021.109420Jarcho, Ingelfinger, Hamel, ; D'agostino, Sr et al., Inhibitors of the Renin-Angiotensin-Aldosterone System and COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMe2012924Khan, Siddique, Shereen, Ali, Liu et al., Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options, J. Clin. Microbiol,
doi:10.1128/JCM.00187-20Kilis-Pstrusinska, Akutko, Braksator, Dancewicz, Grosman-Dziewiszek et al., Kidney Dysfunction and Its Progression in Patients Hospitalized Duo to COVID-19: Contribution to the Clinical Course and Outcomes, J. Clin. Med,
doi:10.3390/jcm10235522Li, De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov
Mackey, King, Gurley, Kiefer, Liederbauer et al., Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review, Ann. Intern. Med,
doi:10.7326/M20-1515Madan, Siglin, Khan, Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic, Cancer Med,
doi:10.1002/cam4.3534Mdtext, Com, None
Ouyang, Lv, Zhong, Wen, Wei et al., Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation, Am. J. Cardiol,
doi:10.1016/j.amjcard.2015.01.013Paar, Wernly, Zhou, Motloch, Hoppe et al., Anti-coagulation for COVID-19 treatment: Both anti-thrombotic and anti-inflammatory?, J. Thromb. Thrombolysis,
doi:10.1007/s11239-020-02212-6Peltzer, Manocha, Ying, Kirzner, Ip et al., Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19, J. Cardiovasc. Electrophysiol,
doi:10.1111/jce.14770Pollard, Blanco, Pollard, Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, with Implications for COVID-19 Therapy, Vivo,
doi:10.21873/invivo.12221Ramakrishnan, Nicolau, Jr, Langford, Mahdi et al., Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial, Lancet Respir. Med,
doi:10.1016/S2213-2600(21)00160-0Reynolds, Adhikari, Pulgarin, Troxel, Iturrate et al., Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2008975Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area, JAMA
Salah, Mehta, Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19, Am. J. Cardiol
Sammalkorpi, Valtonen, Kerttula, Nikkilä, Taskinen, Changes in serum lipoprotein pattern induced by acute infections, Metabolism,
doi:10.1016/0026-0495(88)90120-5Seon, Kim, Hong, Lim, Oh, Risk of COVID-19 diagnosis and death in patients with mental illness: A cohort study, Epidemiol. Psychiatr. Sci,
doi:10.1017/S2045796021000597Singh, Edwards, Gout management and outcomes during the COVID-19 pandemic: A cross-sectional internet survey, Ther. Adv. Musculoskelet Dis,
doi:10.1177/1759720X20966124Sriram, Insel, A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance, Br. J. Pharmacol,
doi:10.1111/bph.15082Team, RStudio: Integrated Development Environment for R. RStudio
Thompson, Nguyen, Noble, Aronoff, COVID-19-related disease severity in pregnancy, Am. J. Reprod. Immunol,
doi:10.1111/aji.13339Vamos, Erath, Benz, Lopes, Hohnloser, Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update, Am. J. Cardiol,
doi:10.1016/j.amjcard.2018.09.036Vamos, Erath, Hohnloser, Digoxin-associated mortality: A systematic review and meta-analysis of the literature, Eur. Heart J,
doi:10.1093/eurheartj/ehv143Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Wang, Zhang, Chen, Wang, Zhang et al., Digoxin Is Associated with Increased All-Cause Mortality in Patients with Atrial Fibrillation Regardless of Concomitant Heart Failure: A Meta-Analysis, J. Cardiovasc. Pharmacol,
doi:10.1097/FJC.0000000000000274Zhang, Penninger, Li, Zhong, Slutsky, Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target, Intensive Care Med,
doi:10.1007/s00134-020-05985-9Zhang, Zhu, Cai, Lei, Qin et al., Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19, Circ. Res,
doi:10.1161/CIRCRESAHA.120.317134Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3{ 'indexed': {'date-parts': [[2022, 1, 20]], 'date-time': '2022-01-20T07:17:16Z', 'timestamp': 1642663036162},
'reference-count': 61,
'publisher': 'MDPI AG',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2022, 1, 8]],
'date-time': '2022-01-08T00:00:00Z',
'timestamp': 1641600000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Pharmaceuticals'],
'abstract': '<jats:p>Data from several cohorts of coronavirus disease 2019 (COVID-19) suggest that the '
'most common comorbidities for severe COVID-19 disease are the elderly, high blood pressure, '
'and diabetes; however, it is not currently known whether the previous use of certain drugs '
'help or hinder recovery. This study aims to explore the association of previous '
'hospitalisation use of medication on the mortality of COVID-19 disease. A retrospective '
'case-control from two hospitals in Madrid, Spain, included all patients aged 18 years or '
'above hospitalised with a diagnosis of COVID-19. A Propensity Score matching (PSM) analysis '
'was performed. Confounding variables were considered to be age, sex, and the number of '
'comorbidities. Finally, 3712 patients were included. Of these, 687 (18.5%) patients died '
'(cases). The 22,446 medicine trademarks used previous to admission were classified according '
'to the ATC, obtaining 689 final drugs; all of them were included in PSM analysis. Eleven '
'drugs displayed a reduction in mortality: azithromycin, bemiparine, budesonide-formoterol '
'fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine '
'theophylline acetate, oral rehydration salts, and salbutamol sulphate. Eight final drugs '
'displayed an increase in mortality: acetylsalicylic acid, digoxin, folic acid, mirtazapine, '
'linagliptin, enalapril, atorvastatin, and allopurinol. Medication associated with survival '
'(anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and '
'inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with '
'mortality show an interaction with the underlying conditions.</jats:p>',
'DOI': '10.3390/ph15010078',
'type': 'journal-article',
'created': {'date-parts': [[2022, 1, 10]], 'date-time': '2022-01-10T04:06:15Z', 'timestamp': 1641787575000},
'page': '78',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'A Case-Control of Patients with COVID-19 to Explore the Association of Previous '
'Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score '
'Matching Analysis'],
'prefix': '10.3390',
'volume': '15',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-9100-3324',
'authenticated-orcid': False,
'given': 'Jaime',
'family': 'Monserrat Villatoro',
'sequence': 'first',
'affiliation': []},
{'given': 'Gina', 'family': 'Mejía-Abril', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lucía', 'family': 'Díaz García', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-6150-4320',
'authenticated-orcid': False,
'given': 'Pablo',
'family': 'Zubiaur',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-4925-731X',
'authenticated-orcid': False,
'given': 'María',
'family': 'Jiménez González',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Guillermo',
'family': 'Fernandez Jimenez',
'sequence': 'additional',
'affiliation': []},
{'given': 'Inés', 'family': 'Cancio', 'sequence': 'additional', 'affiliation': []},
{'given': 'José Ramón', 'family': 'Arribas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Carmen', 'family': 'Suarez Fernández', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6173-5711',
'authenticated-orcid': False,
'given': 'Jesús',
'family': 'Mingorance',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-3771-8740',
'authenticated-orcid': False,
'given': 'Julio',
'family': 'García Rodríguez',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'José Ramón',
'family': 'Villagrasa Ferrer',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-1823-4174',
'authenticated-orcid': False,
'given': 'Antonio J.',
'family': 'Carcas',
'sequence': 'additional',
'affiliation': []},
{'given': 'Jesús', 'family': 'Frías', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-6519-8885',
'authenticated-orcid': False,
'given': 'Francisco',
'family': 'Abad-Santos',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-8584-3263',
'authenticated-orcid': False,
'given': 'Alberto M.',
'family': 'Borobia',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4052-8876',
'authenticated-orcid': False,
'given': 'Elena',
'family': 'Ramírez',
'sequence': 'additional',
'affiliation': []},
{ 'name': 'on behalf of the COVID@HULP Working Group and Other Collaborators from Hospital '
'Universitario de la Princesa',
'sequence': 'additional',
'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2022, 1, 8]]},
'reference': [ {'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2010419'},
{'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.6775'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm6915e3'},
{'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.1585'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30183-5'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2002032'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-05985-9'},
{'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2008975'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMe2012924'},
{'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/CIRCRESAHA.120.317134'},
{'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.04.07.20056788'},
{'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/d41573-020-00016-0'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.5582/bst.2020.01020'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JCM.00187-20'},
{'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.10480'},
{'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.amjmed.2019.08.055'},
{'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jce.14770'},
{'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.21873/invivo.12221'},
{'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-020-72879-7'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/eurheartj/ehv143'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/FJC.0000000000000274'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.amjcard.2015.01.013'},
{'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.amjcard.2018.09.036'},
{'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.nut.2020.111016'},
{'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/aji.13339'},
{ 'key': 'ref27',
'unstructured': 'Technical Data Sheet Mirtazapina '
'Cinfa®https://cima.aemps.es/cima/dochtml/ft/67068/FT_67068.html'},
{ 'key': 'ref28',
'unstructured': 'Technical Data Sheet '
'Qudix®https://cima.aemps.es/cima/dochtml/ft/70169/FT_70169.html'},
{'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.d4551'},
{'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1017/S2045796021000597'},
{ 'key': 'ref31',
'unstructured': 'Technical Data Sheet '
'Trajenta®https://cima.aemps.es/cima/dochtml/ft/11707004/FT_11707004.html'},
{'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/jcm10235522'},
{'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31030-8'},
{'key': 'ref34', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M20-1515'},
{'key': 'ref35', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bph.15082'},
{'key': 'ref36', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijcrp.2021.200121'},
{ 'key': 'ref37',
'series-title': 'Endotext [Internet]',
'article-title': 'Lipid and Lipoprotein Levels in Patients with COVID-19 Infections',
'author': 'Feingold',
'year': '2020'},
{'key': 'ref38', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0026-0495(88)90120-5'},
{ 'key': 'ref39',
'unstructured': 'Technical Data Sheet '
'Veklury®https://cima.aemps.es/cima/dochtml/ft/1201459002/FT_1201459002.html'},
{ 'key': 'ref40',
'unstructured': 'Technical Data Sheet '
'Kaletra®https://cima.aemps.es/cima/dochtml/ft/01172006/FT_01172006.html'},
{ 'key': 'ref41',
'unstructured': 'Technical Data Sheet '
'Roactemra®https://cima.aemps.es/cima/dochtml/ft/108492007/FT_108492007.html#4-datos-cl-nicos'},
{'key': 'ref42', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1759720X20966124'},
{'key': 'ref43', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cam4.3534'},
{'key': 'ref44', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.amjcard.2020.12.073'},
{'key': 'ref45', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11239-020-02212-6'},
{'key': 'ref46', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14787210.2020.1813024'},
{'key': 'ref47', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1777904'},
{'key': 'ref48', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1761882'},
{'key': 'ref49', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1764392'},
{'key': 'ref50', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(20)30314-3'},
{'key': 'ref51', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00160-0'},
{'key': 'ref52', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cbi.2021.109420'},
{'key': 'ref53', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/1440-1681.13488'},
{ 'key': 'ref54',
'unstructured': 'Royal Decree 1090/2015, of 4 December, Regulating Clinical Trials with '
'Medicinal Products, Ethics Committees for Investigation with Medicinal '
'Products and the Spanish Clinical Studies '
'Registryhttps://www.aemps.gob.es/legislacion/espana/investigacionClinica/docs/Royal-Decree-1090-2015_4-December.pdf'},
{ 'key': 'ref55',
'unstructured': 'Organic Law 3/2018 of 5 December 2018, on the Protection of Personal '
'Data and Guarantee of Digital '
'Rightshttps://noticias.juridicas.com/base_datos/Laboral/632849-lo-3-2018-de-5-dic-proteccion-de-datos-personales-y-garantia-de-los-derechos.html'},
{ 'key': 'ref56',
'unstructured': 'nCoV Case Records form Version '
'1.3https://media.tghn.org/medialibrary/2020/03/ISARIC_COVID-19_CRF_V1.3_24Feb2020.pdf'},
{'key': 'ref57', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/jcm9061733'},
{ 'key': 'ref58',
'unstructured': 'ATC/DDD Index 2020 Updated 16 December '
'2019https://www.whocc.no/atc_ddd_index/>'},
{ 'key': 'ref59',
'unstructured': 'Drugbank Pharmaceutical Knowledge Base that is Enabling Major Advances '
'across the Data-Driven Medicine Industryhttps://www.drugbank.ca/drugs'},
{'key': 'ref60', 'unstructured': 'https://www.R-project.org/'},
{ 'key': 'ref61',
'unstructured': 'RStudio: Integrated Development Environment for '
'Rhttp://www.rstudio.com/'}],
'container-title': ['Pharmaceuticals'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/1424-8247/15/1/78/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 1, 20]],
'date-time': '2022-01-20T02:34:16Z',
'timestamp': 1642646056000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1, 8]]},
'references-count': 61,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 1]]}},
'alternative-id': ['ph15010078'],
'URL': 'http://dx.doi.org/10.3390/ph15010078',
'relation': {},
'ISSN': ['1424-8247'],
'issn-type': [{'value': '1424-8247', 'type': 'electronic'}],
'subject': ['Drug Discovery', 'Pharmaceutical Science', 'Molecular Medicine'],
'published': {'date-parts': [[2022, 1, 8]]}}
